MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results